Interleukin-33 Expression is Specifically Enhanced in Inflamed Mucosa of Ulcerative Colitis

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2010 Apr 21

PMID 20405148

Citations 135

Authors

Ayako Kobori

Yuhki Yagi

Hirotsugu Imaeda

Hiromitsu Ban

Shigeki Bamba

Tomoyuki Tsujikawa

Yasuharu Saito

Yoshihide Fujiyama

Akira Andoh

Affiliations

Soon will be listed here.

Abstract

Background: Interleukin (IL)-33 is a cytokine belonging to the IL-1 family. IL-33 has been shown to elicit a Th2-like cytokine response in immune cells. In this study, we investigated IL-33 expression in the inflamed mucosa of patients with inflammatory bowel disease (IBD), and characterized the molecular mechanisms responsible for IL-33 expression in human colonic subepithelial myofibroblasts (SEMFs).

Methods: IL-33 mRNA expression was determined by real-time polymerase chain reaction (PCR). IL-33 expression in the IBD mucosa was evaluated by immunohistochemical methods.

Results: IL-33 mRNA expression was significantly elevated in active lesions from patients with ulcerative colitis (UC), but was not detected in inactive lesions from UC patients or in lesions from patients with either active or inactive Crohn's disease. Colonic SEMFs were identified as a major source of IL-33 in the mucosa. IL-1β and tumor necrosis factor-α (TNF-α) significantly enhanced IL-33 mRNA and protein expression in isolated colonic SEMFs. IL-1β and TNF-α did not affect IL-33 expression in intestinal epithelial cell lines (HT-29 and Caco-2 cells). This IL-1β- and TNF-α-induced IL-33 mRNA expression was mediated by p42/44 mitogen activated protein kinase (MAPK) pathway-dependent activation of nuclear factor (NF)-κB and activator protein (AP)-1.

Conclusions: IL-33, derived from colonic SEMFs, may play an important role in the pathophysiology of UC.

Citing Articles

Key Interleukins in Inflammatory Bowel Disease-A Review of Recent Studies.

Aebisher D, Bartusik-Aebisher D, Przygorzewska A, Oles P, Woznicki P, Kawczyk-Krupka A Int J Mol Sci. 2025; 26(1.

PMID: 39795980 PMC: 11719876. DOI: 10.3390/ijms26010121.

Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease.

Arnold I, Munitz A Nat Rev Immunol. 2024; 24(12):858-877.

PMID: 38982311 DOI: 10.1038/s41577-024-01048-y.

Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression.

Park J, Mortaja M, Son H, Zhao X, Sloat L, Azin M Nat Commun. 2024; 15(1):4099.

PMID: 38816352 PMC: 11139893. DOI: 10.1038/s41467-024-48441-8.

The role of interleukin-33 in organ fibrosis.

Di Carmine S, Scott M, McLean M, McSorley H Discov Immunol. 2024; 1(1):kyac006.

PMID: 38566909 PMC: 10917208. DOI: 10.1093/discim/kyac006.

Fibrosis in IBD: from pathogenesis to therapeutic targets.

Rieder F, Mukherjee P, Massey W, Wang Y, Fiocchi C Gut. 2024; 73(5):854-866.

PMID: 38233198 PMC: 10997492. DOI: 10.1136/gutjnl-2023-329963.

References

Nishida A, Andoh A, Imaeda H, Inatomi O, Shiomi H, Fujiyama Y . Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut. 2009; 59(4):531-41. DOI: 10.1136/gut.2009.193599. View

Best W, Becktel J, SINGLETON J . Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979; 77(4 Pt 2):843-6. View

Sanada S, Hakuno D, Higgins L, Schreiter E, McKenzie A, Lee R . IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007; 117(6):1538-49. PMC: 1865027. DOI: 10.1172/JCI30634. View

Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko A . Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009; 183(8):5094-103. DOI: 10.4049/jimmunol.0802387. View

Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B . Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005; 129(2):550-64. DOI: 10.1016/j.gastro.2005.05.002. View

Mahida Y, Beltinger J, Makh S, Goke M, Gray T, Podolsky D . Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol. 1998; 273(6):G1341-8. DOI: 10.1152/ajpgi.1997.273.6.G1341. View

Cuenda A, Rouse J, Doza Y, Meier R, Cohen P, Gallagher T . SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995; 364(2):229-33. DOI: 10.1016/0014-5793(95)00357-f. View

Wood I, Wang B, Trayhurn P . IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009; 384(1):105-9. DOI: 10.1016/j.bbrc.2009.04.081. View

Sands B . Inflammatory bowel disease: past, present, and future. J Gastroenterol. 2007; 42(1):16-25. PMC: 2780674. DOI: 10.1007/s00535-006-1995-7. View

10.

Ho L, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M . IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol. 2007; 82(6):1481-90. DOI: 10.1189/jlb.0407200. View

11.

Ding S, Olekhnovich I, Cover T, Peek Jr R, Smith Jr M, Goldberg J . Helicobacter pylori and mitogen-activated protein kinases mediate activator protein-1 (AP-1) subcomponent protein expression and DNA-binding activity in gastric epithelial cells. FEMS Immunol Med Microbiol. 2008; 53(3):385-94. PMC: 2553690. DOI: 10.1111/j.1574-695X.2008.00439.x. View

12.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan T . IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23(5):479-90. DOI: 10.1016/j.immuni.2005.09.015. View

13.

Yasumoto H, Kim S, Zhan Y, Miyazaki H, Hoshiga M, Kaneda Y . Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats. Gene Ther. 2002; 8(22):1682-9. DOI: 10.1038/sj.gt.3301590. View

14.

Bouma G, Strober W . The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003; 3(7):521-33. DOI: 10.1038/nri1132. View

15.

Mayer L . Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2009; 45(1):9-16. DOI: 10.1007/s00535-009-0138-3. View

16.

Marvie P, Lisbonne M, LHelgoualch A, Rauch M, Turlin B, Preisser L . Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med. 2009; 14(6B):1726-39. PMC: 3829034. DOI: 10.1111/j.1582-4934.2009.00801.x. View

17.

Favata M, Horiuchi K, Manos E, Daulerio A, Stradley D, Feeser W . Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998; 273(29):18623-32. DOI: 10.1074/jbc.273.29.18623. View

18.

Fang J, Ding M, Yang L, Liu L, Jiang B . PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007; 19(12):2487-97. PMC: 2094004. DOI: 10.1016/j.cellsig.2007.07.025. View

19.

Alessi D, Cuenda A, Cohen P, Dudley D, Saltiel A . PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995; 270(46):27489-94. DOI: 10.1074/jbc.270.46.27489. View

20.

Mukhopadhyay S, Mukherjee S, Smith M, Das S . Activation of MAPK/AP-1 signaling pathway in lung injury induced by 2-chloroethyl ethyl sulfide, a mustard gas analog. Toxicol Lett. 2008; 181(2):112-7. DOI: 10.1016/j.toxlet.2008.07.005. View